Related Experiment Video
Updated: May 2, 2026
A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
Published on: September 30, 2021
Is reduction of tumor burden sufficient for the 21st century?
George Nahas1, Sarah A Bliss2, Garima Sinha3
1Department of Medicine, Hematology/Oncology, New Jersey Medical School, Rutgers Univ., Newark, NJ, USA.
Abstract:
Currently, animal models are used to test the efficacy of tumor treatment. A significant reduction of tumor mass is lauded as great improvement. As we begin the 21st century, one wonders if this is sufficient and acceptable for cancer treatment. Although the presence of cancer stem cell (CSCs) is not a new phenomenon, their role in the initiation of the tumor for clinical resurgence is mostly ignored when testing drugs. The current treatment then poses a major limitation to aggressively target the cells most responsible for tumor initiation and resurgence. The review does not trivialize the problem since it is acknowledged that the tumors and cells within the tissue microenvironment would interact through complex mechanisms. It is quite possible that the interaction by CSCs and the microenvironment will vary, depending on the tissue, e.g., bone marrow versus brain. Research studies are needed to investigate if CSCs from the same organ differ after migrating to other tissues. If so, this will pose an economic dilemma for targeted drug development. It will not be feasible to develop drugs for each organ. Besides, the cost, there could be problems to effectively deliver the drugs to all organs, problems to assess drug distribution to particular tissues and toxicity for specific drugs. If multiple drugs are required to eradicate CSCs in different tissues, there is a problem of possible untoward effect for the simultaneous delivery of multiple drugs to a single cancer patient. As new drugs are developed, the investigators will need to pay attention for dedifferentiation of non-CSCs to CSCs. The metabolic pathways will have to be given equal attention as the stem cells genes since their pathways might show major differences rather than the stem cells genes, which are shared by the normal stem cells.
Insights
Current cancer treatments often overlook cancer stem cells (CSCs), which drive tumor regrowth. New drug development must target CSCs and their unique metabolic pathways for effective cancer therapy.
Area of Science:
- Oncology
- Cancer Biology
- Drug Development
Background:
- Traditional tumor treatment efficacy is often measured by tumor mass reduction, potentially overlooking critical factors in cancer recurrence.
- Cancer stem cells (CSCs) play a significant role in tumor initiation and clinical resurgence, yet their targeting is often neglected in drug efficacy testing.
Purpose of the Study:
- To highlight the limitations of current cancer treatment models that do not adequately address cancer stem cells (CSCs).
- To discuss the challenges and economic implications of developing targeted therapies for CSCs across different tissue microenvironments.
- To emphasize the need to consider CSC dedifferentiation and metabolic pathway variations in future drug development.
Main Methods:
- Review of existing literature on cancer stem cell biology and tumor microenvironment interactions.
- Analysis of the limitations in current animal models for assessing cancer treatment efficacy.
- Discussion of potential challenges in targeted drug development for CSCs, including tissue specificity, drug delivery, and toxicity.
Main Results:
- Current methods focusing on tumor mass reduction are insufficient for evaluating comprehensive treatment efficacy.
- CSCs are critical drivers of tumor initiation and recurrence, necessitating their inclusion in treatment strategies.
- Significant challenges exist in developing organ-specific CSC therapies due to varying CSC-microenvironment interactions and potential dedifferentiation.
Conclusions:
- Future cancer drug development must prioritize targeting cancer stem cells (CSCs) and their unique metabolic pathways.
- Addressing CSC heterogeneity across different tissue microenvironments is crucial for effective and economically viable targeted therapies.
- Investigating CSC dedifferentiation and metabolic variations is essential for overcoming treatment resistance and improving patient outcomes.
More Related Videos
07:48Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures
Published on: December 26, 2016
07:26Author Spotlight: Creating Human Vascularized Micro-Tumors as Models for Translational Cancer Research
Published on: September 15, 2023
Related Concept Videos
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
01:27Tumor Immunotherapy
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:07Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...